Crinetics Pharmaceuticals (CRNX) Receivables - Accured (2022 - 2026)

Crinetics Pharmaceuticals' Receivables - Accured history runs 5 years deep, the most recent figure standing at $9.0 million for Q1 2026.

• In Q1 2026, Receivables - Accured rose 25.0% year-over-year to $9.0 million; the TTM figure through Mar 2026 stood at $9.0 million (up 25.0% YoY), while the FY2025 annual figure was $7.8 million, down 6.02% from the prior year.
• Receivables - Accured for Q1 2026 stood at $9.0 million, up from $7.8 million in the prior quarter.
• The five-year high for Receivables - Accured was $9.0 million in Q1 2026, with the low at $1.4 million in Q4 2022.
• The 5-year median for Receivables - Accured is $7.5 million (2025), against an average of $6.4 million.
• The sharpest annual moves came in 2024 and 2025: Receivables - Accured surged 167.74% in 2024, then fell 6.02% in 2025.
• Crinetics Pharmaceuticals' Receivables - Accured stood at $1.4 million in 2022, then surged by 121.43% to $3.1 million in 2023, then soared by 167.74% to $8.3 million in 2024, then fell by 6.02% to $7.8 million in 2025, then rose by 15.38% to $9.0 million in 2026.
• Business Quant data shows CRNX's Receivables - Accured at $9.0 million in Q1 2026, $7.8 million in Q4 2025, and $6.3 million in Q3 2025.